Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
|Eligible Ages||12 Years - 17 Years|
- - Participant must be ≥12 to <18 years of age at the time of signing the informed consent/assent according to local regulation.
- - Participant has had a diagnosis of moderate to severe plaque psoriasis (PSO) for at least 3 months prior to the Screening Visit and: 1.
- - Participant must be candidate for systemic PSO therapy and/or photo/chemotherapy.
- - Body weight ≥30 kg and body mass index for age percentile of ≥5 at Baseline.
- - Male or female A female participant will be eligible to participate if she is not pregnant, not breastfeeding, and a woman of childbearing potential (WOCBP) agrees to follow the contraceptive guidance.
- - Capable of giving/having parent(s) or legal representative provide signed informed
consent/assent (where appropriate)
Exclusion Criteria:- Participant has a presence of guttate, inverse, pustular, or erythrodermic PSO or other dermatological condition that may impact the clinical assessment of PSO.
- - Participant has a history of inflammatory bowel disease (IBD) or symptoms suggestive of IBD.
- - History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated.
- - Participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections) - Participant has laboratory abnormalities at Screening.
- - Participant has experienced primary failure to one or more interleukin-17 (IL-17) biologic response modifier OR primary failure to more than 1 biologic response modifier other than an IL-17 biologic response modifier.
- - Presence of active suicidal ideation, or positive suicide behavior.
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
|UCB Biopharma SRL|
The person who is responsible for the scientific and technical direction of the entire clinical study.
|Principal Investigator Affiliation||001 844 599 2273 (UCB)|
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
|Countries||Canada, Poland, United States|
The disease, disorder, syndrome, illness, or injury that is being studied.
|Moderate to Severe Plaque Psoriasis|
Experimental: Bimekizumab Dose A
Study participants randomized to this arm will receive bimekizumab (BKZ) Dose A at pre-specified time points during the study.
Experimental: Bimekizumab Dose B
Study participants randomized to this arm will receive bimekizumab (BKZ) Dose B at pre-specified time points during the study.
Drug: - bimekizumab
Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.